Is Novo Nordisk A/S halal to invest in?

As of August 2026, Novo Nordisk A/S NNOR.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Novo Nordisk A/S a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Novo Nordisk A/S using these criteria to determine its compliance status.

Can Muslims buy shares of Novo Nordisk A/S?

Muslim investors may consider investing in Novo Nordisk A/S if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Novo Nordisk A/S classified as HALAL?

Musaffa determines the Shariah status of Novo Nordisk A/S by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Novo Nordisk A/S updated?

The Shariah compliance status of Novo Nordisk A/S may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Novo Nordisk A/S become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Novo Nordisk A/S?

You can check the latest Shariah compliance status of Novo Nordisk A/S on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Novo Nordisk A/S NNOR.VI

Last Updated: Aug 17, 12:00 AM·WBAG

NNOR.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Novo Nordisk A/S is classified as halal.

HALAL

Report Source: undefined Quarter Report

Novo Nordisk A/S. Stock Analysis NNOR.VI

Austria Health Care Mega Cap

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.